Analysis of Laboratory Markers for Severe COVID-19

CompletedOBSERVATIONAL
Enrollment

193

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions
Coronavirus Infection COVID-19
Interventions
DIAGNOSTIC_TEST

CT of the chest organs, blood biochemical parameters

Taking into account the clinical manifestations, all patients underwent chest computed tomography (CT) to diagnose COVID-19-associated pneumonia. According to the CT results, all patients were classified into one of 4 subgroups, according to the degree of pulmonary infiltration. The following biochemical parameters were selected and used to monitor dynamics: procalcitonin (PCT), C-reactive protein (CRP), D-dimer (DD), ferritin (FRT). Biochemical markers were determined daily during the stay in the intensive care unit. The duration of observation was 15 days was selected. Information was analysed retrospectively.

Trial Locations (1)

100008

Karaganda Medical University, Karaganda

All Listed Sponsors
lead

Karaganda Medical University

OTHER

NCT06460753 - Analysis of Laboratory Markers for Severe COVID-19 | Biotech Hunter | Biotech Hunter